Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of PENTAXIM in Philippines
NCT00254917Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2003
- Primary completion
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Sanofi. Primary endpoint: Safety of PENTAXIM™ Vaccine at 20 months. Started Oct 2003; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00254917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254917.